159
Participants
Start Date
May 30, 2024
Primary Completion Date
March 31, 2026
Study Completion Date
September 30, 2026
AOC 1001 (del-desiran)
Del-desiran will be administered by intravenous (IV) infusion.
Placebo
Placebo will be administered by intravenous (IV) infusion.
Rigshospitalet, Copenhagen
Aarhus University Hospital, Aarhus N
University of Rochester Medical Center, Rochester
University of Pennsylvania, Philadelphia
Hospital Universitario Donostia, Donostia / San Sebastian
Fondazione Serena Onlus - Centro Clinico NeMO Milano, Milan
Kennedy Krieger Institute, Baltimore
Virginia Commonwealth University, Richmond
Wake Forest, Winston-Salem
Duke University Medical Center, Durham
University of Florida, Gainesville
University Research Center of South Florida, Tampa
Ohio State University, Columbus
University of Cincinnati Gardner Neuroscience Institute, Cincinnati
Indiana University (IU), Indianapolis
University of Minnesota, Minneapolis
Kansas University Medical Center, Kansas City
AP-HP Hopital Pitie-Salpetriere, Paris
Houston Methodist Neurological Institute, Houston
University of Colorado, Denver
Klinikum der Ludwig-Maximilians-Universitaet Muenchen, Munich
Stanford University, Stanford
University of Washington, Seattle
Beth Israel Deaconess Medical Center, Boston
The Ottawa Hospital, Ottawa
Montreal Neurological Institute, Montreal
Aomori Hospital, Aomori
National Hospital Organization Osaka Toneyama Medical Center, Osaka
Osaka University Hospital, Osaka
National Center of Neurology and Psychiatry, Tokyo
Maastricht University Medical Center, Maastricht
Stichting Radboud Universitair Medisch Centrum, Nijmegen
University College London Hospital, London
St. Georges University Hospitals NHS Foundation Trust, London
Lead Sponsor
Avidity Biosciences, Inc.
INDUSTRY